We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Biotech and Biomed Researchers to Benefit from Imaging Companies Merger

By LabMedica International staff writers
Posted on 23 Mar 2010
The integration of two highly regarded manufacturers of imaging and microscopy systems is designed to provide scientists and clinicians in the biomedical and biotechnical fields with the best options for imaging and intelligent image analysis.

The actors in this endeavor are Leica Microsystems (Wetzlar, Germany), which has acquired Genetix Ltd. More...
(New Milton, United Kingdom).

Leica Microsystems is a leading global designer and producer of innovative, high technology, precision optical systems for the analysis of microstructures. It is a market leader in the fields of microscopy, confocal laser scanning microscopy, and corresponding imaging systems, specimen preparation and medical equipment.

Genetix has established industry standards in areas such as picking microbial colonies for genomic studies or screening and selection of mammalian cell lines. Other Genetix systems use imaging platforms to monitor cell growth, evaluate cellular response, and quantify tissue biomarkers. Genetix will exist as a separate business unit within Leica Microsystems and will continue to market its products through existing channels. Customer services such as product ordering, applications support, and instrument service will remain unchanged.

Stefan Traeger, managing director of the life science division at Leica Microsystems, said, "Genetix's extensive expertise will be invaluable for us. Their software capabilities, specifically in analytical software, will help us to make progress in the area of virtual microscopy, which is a field we have only recently stepped into. In addition, Genetix's experience and market leading products in cell biology and genetics will expand our reach into the drug discovery and development markets.”

Charles de Rohan, head of the Genetix business unit within Leica Microsystems, said,
"Joining together with Leica Microsystems gives Genetix greater access to global markets and increased financial resources to achieve its growth plans. Over the past decade, Genetix has been building its presence in the life sciences, diagnostics, and digital pathology segments through a combination of internal product development and acquisitions. Combining our strengthening presence with Leica Microsystems' R&D capabilities, greater resources, and global reach is in the best interests of our shareholders, customers, and employees and will maximize the potential of our innovative technology.”

Related Links:
Leica Microsystems
Genetix Ltd.



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.